Galmed Pharmaceuticals

Company Overview

Snapshot

Founded in January 2000, Galmed Pharmaceuticals operates with 1–10 employees and has raised a total of $150.3 million across 5 public funding rounds. The company recently announced meaningful top-line results from its AM-001 study of Aramchol Meglumine in November 2025.

Business overview

Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for liver, metabolic, and inflammatory diseases. Its core product, Aramchol, is a lead drug candidate currently undergoing a Phase 3 registrational study for the treatment of NASH and fibrosis. The company also collaborates with the Hebrew University on Amilo-5MER, a 5 amino acid synthetic peptide, and is expanding its activities into cancer and major cardiometabolic diseases, operating within the Health Tech & Life Sciences sector.

Strategic signal

In May 2026, Galmed Pharmaceuticals announced a collaboration with Tissue Dynamics to develop a human-centered chronic cardiac fibrosis platform to advance Aramchol-based therapeutics. This partnership signals a strategic expansion of Aramchol's potential applications beyond liver diseases into cardiac conditions, indicating a broader market opportunity and diversification of its pipeline for investors.

Company Intelligence Q&A

What was a significant recent development regarding Aramchol's formulation?

In May 2026, Galmed Pharmaceuticals announced results from a first-in-man pharmacokinetics study of an oral formulation of Aramchol Meglumine (AM), demonstrating that 400mg AM increases bioavailability by approximately 500% compared to Aramchol Free Acid (AA) 300mg.

What strategic partnership did Galmed Pharmaceuticals announce in May 2026?

In May 2026, Galmed Pharmaceuticals partnered with Tissue Dynamics Ltd. to develop a human-centered chronic cardiac fibrosis platform, aiming to advance Aramchol-based therapeutics for cardiac conditions.

What were the key findings from Aramchol's oncology studies in November 2025?

In November 2025, Galmed Pharmaceuticals announced top-line results from oncology studies, showing that a three-drug combination of Aramchol, Stivarga, and Metformin significantly enhanced GI tumor cell killing both in-vivo and in-vitro.

What was the outcome of the AM-001 study of Aramchol Meglumine in November 2025?

In November 2025, Galmed Pharmaceuticals announced meaningful top-line results from its AM-001 study of Aramchol Meglumine.

What was a recent financial reporting milestone for Galmed Pharmaceuticals?

In March 2026, Galmed Pharmaceuticals Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.